Want to join the conversation?
Deutsche Bank analyst Mario Contreras questions about the revenue management initiatives. $K says that it had a significant benefit in price realization and what was called a volume-to-value model orientation. The company intends to bring back this orientation to focus on price mix, which been lagging for a few years.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?